IR News



LANXESS product Rely[†]On Virkon effective against coronavirus

- Stronger demand in Asia and Europe
- Optimization of production capacities for increased delivery capability
- Effectiveness of Rely⁺On Virkon scientifically proven

Cologne – The coronavirus continues to spread. Authorities around the world are therefore tightening measures to stop the further spread of the lung disease. With no vaccine available, disinfection is of the utmost importance.

The high level disinfectant Rely⁺On Virkon from specialty chemicals company LANXESS is effective against the coronavirus. The product is used for hard surface and equipment disinfection. Anneliese Bischof, Head of the Disinfectants Business at LANXESS: "Following the outbreak of the coronavirus, we are seeing increased demand for Rely⁺On Virkon in China and other countries around the globe. We are therefore currently working intensively to optimally align our production and logistics capacities to deliver additional product quantity to this region as quickly as possible."

Rely[†]On Virkon inactivates coronavirus quickly

Independent tests have proven that Rely⁺On Virkon inactivates a closely related surrogate of the currently spreading coronavirus strain. "From these tests it can be concluded that Rely⁺On Virkon is also effective against 2019-nCoV," Bischof said.

In independent tests Rely⁺On Virkon achieved inactivation of the coronavirus strain at a 1:100 dilution rate with a 10-minute contact time. This corresponds to test conditions required by the U.S. Environmental Protection Agency (EPA) and proves the performance and suitability of Rely⁺On Virkon for practical use.

LANXESS AG

Investor Relations 50569 Cologne Germany

Phone: +49 221 8885 3262 Fax: +49 221 8885 4944

Page 1 of 2

IR News



Rely[†]On Virkon is diluted for application and sprayed on hard surfaces and equipment. It can therefore help to reduce the risk of contamination of surfaces, door handles, tables or chairs during disinfection measures at public transport terminals, airports, hospitals, clinics, shopping malls, etc.

LANXESS produces a wide range of scientifically based biocide technologies under the Virkon brand. Virkon is manufactured by the LANXESS Material Protection Products business unit. The business unit belongs to LANXESS's Performance Chemicals segment, with sales of 1.35 billion euros in 2018.

LANXESS is a leading specialty chemicals company with sales of EUR 7.2 billion in 2018. The company currently has about 15,500 employees in 33 countries and is represented at 57 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Cologne, February 3, 2020

Forward-Looking Statements

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

LANXESS AG

Investor Relations 50569 Cologne Germany

Phone: +49 221 8885 3262 Fax: +49 221 8885 4944

Page 2 of 2